Health TrialsbyHealthPanel

qCON/qNOX-Guided Anesthesia in Patients Undergoing Thyroidectomy Surgery

ConditionsThyroid SurgeriesIntraoperative Analgesic UseAnesthesia Depth Monitoring
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorKayseri City Hospital

About this trial

The aim of this study is to evaluate the effect of using the non-invasive Conox monitor on intraoperative opioid consumption. Additionally, the study aims to assess the impact of Conox monitoring on recovery time, postoperative agitation rate, and pain scores, and to investigate the correlation between qCON and qNOX values and conventional hemodynamic parameters.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients aged 18-70 years

Thyroidectomy cases with ASA physical status I-II

Patients who have provided written informed consent

Disqualifiers

Skin lesions preventing EEG electrode placement

Neurological disorders (e.g., epilepsy)

Anticipated difficult airway

Trial design

Design model

Parallel

Treatments tested in this trial

  • Connox EEG Monitoring

    Device

    Conox EEG monitor will be applied intraoperatively. Anesthetic and opioid titration will be guided by qCON values between 40-60 and qNOX values between 30-60. Opioid administration will be adjusted according to qNOX levels in addition to standard clinical monitoring.

  • standard anesthesia management

    Other intervention

    Standard anesthesia management will be performed according to routine clinical practice. Opioid titration will be guided by conventional hemodynamic parameters including heart rate and mean arterial pressure. No EEG-based monitoring will be used for analgesia titration.

Treatment groups

90 Participants
are divided into 2 treatment groups
Group A: ConoxExperimental treatment 1 intervention
Group B: controlActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Total intraoperative opioid consumption

Total intraoperative opioid consumption will be defined as the cumulative dose of remifentanil (µg/kg) administered from induction of anesthesia until completion of surgery (skin closure). Data will be obtained from anesthesia records and analyzed comparatively between the study groups.

Time frame
Intraoperative period

Secondary outcomes

1

Correlation between qCON/qNOX values and hemodynamic parameters

The correlation between qCON and qNOX indices and hemodynamic parameters (heart rate and mean arterial pressure) will be evaluated during the intraoperative period. Values will be recorded at predefined intervals and analyzed using correlation analysis.

Time frame
Intraoperative period
2

Postoperative pain scores

Postoperative pain intensity will be assessed using the Visual Analog Scale(VAS), A 0 to 10 numerical rating scale, where 0 indicates no pain and 10 indicates the worst imaginable pain. Pain scores will be recorded every five minutes during the first 30 minutes in the post-anesthesia care unit (PACU).

Time frame
Within the first 30 minutes after surgery in the PACU (assessed every 5 minutes)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Kayseri City Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now